What's Happening?
Humana has affirmed its financial outlook for 2026, despite facing challenges related to its Medicare Advantage (MA) star ratings. The company's shares fell premarket due to uncertainties surrounding future star ratings performance. Humana reported a Q1
profit of $1.19 billion, slightly down from the previous year, but revenue increased to $39.6 billion from $32.1 billion. The company expects to earn at least $9 per share in 2026 and projects a medical loss ratio (MLR) of 92.75%. Humana's Medicare Advantage membership is anticipated to grow by 25% compared to 2025. However, the decline in star ratings could impact quality bonus payments and revenues.
Why It's Important?
The star ratings are crucial for Humana as they affect the company's quality bonus payments from the Centers for Medicare & Medicaid Services (CMS). A decline in these ratings could significantly impact Humana's revenues and operating results. The company's ability to maintain or improve its star ratings is vital for its financial health and competitive position in the Medicare Advantage market. The projected growth in membership and revenue highlights Humana's strong market presence, but the star ratings challenge poses a risk to its financial performance and strategic goals.
What's Next?
Humana is appealing a court decision that rejected its challenge to the star ratings. The outcome of this appeal will be critical in determining the company's future financial performance. Humana will need to focus on improving its star ratings to secure quality bonus payments and maintain its competitive edge. The company is also working on adapting to potential changes in MA rates and managing the higher acuity of new members, which could affect costs and MLR.
